CN111956547A - 一种抗炎舒缓类组合物及其应用 - Google Patents
一种抗炎舒缓类组合物及其应用 Download PDFInfo
- Publication number
- CN111956547A CN111956547A CN202010853665.2A CN202010853665A CN111956547A CN 111956547 A CN111956547 A CN 111956547A CN 202010853665 A CN202010853665 A CN 202010853665A CN 111956547 A CN111956547 A CN 111956547A
- Authority
- CN
- China
- Prior art keywords
- parts
- inflammatory
- soothing
- skin care
- care product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 240000007232 Illicium verum Species 0.000 claims abstract description 14
- 235000008227 Illicium verum Nutrition 0.000 claims abstract description 14
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 11
- 239000001292 pimpinella anisum fruit oil Substances 0.000 claims abstract description 8
- 229940074065 star anise fruit extract Drugs 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 16
- 239000004519 grease Substances 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 11
- 239000003906 humectant Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- -1 Magnetitum Chemical compound 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 claims description 2
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 2
- 244000025272 Persea americana Species 0.000 claims description 2
- 235000008673 Persea americana Nutrition 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 244000044822 Simmondsia californica Species 0.000 claims description 2
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 229940032067 peg-20 stearate Drugs 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 229940047670 sodium acrylate Drugs 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 229940100459 steareth-20 Drugs 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 11
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000007794 irritation Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000003837 chick embryo Anatomy 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 230000003467 diminishing effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 4
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 4
- 230000035618 desquamation Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000009048 phenolic acids Nutrition 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- 229930006739 camphene Natural products 0.000 description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000010676 star anise oil Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗炎舒缓组合物,属于护肤领域。所述抗炎舒缓组合物包含以下重量份的组分:八角茴香果提取物20‑60份、八角茴香籽油1‑5份和青钱柳叶提取物10‑40份。另外,本发明还提供了一种包含抗炎舒缓组合物的抗炎舒缓类护肤品,本发明公开的抗炎舒缓类护肤品采用植物组分,消炎抗菌的效果相对温和有效,有很好的应用前景。
Description
技术领域
本发明涉及一种护肤领域,尤其是一种抗炎舒缓类组合物及其应用。
背景技术
人体脸部每天都会受到光、热、空气污染、气候、细菌感染等外部原因,或者是人体内分泌失调等内在因素引起的炎症,一般情况下炎症会导致毛孔粗大、红肿、刺痛,瘙痒,长粉刺、长痘痘等不良影响。
因此消炎抑菌的护肤品备受大家青睐,植物组分消炎抗菌相对温和有效也广受消费者欢迎。
发明内容
基于此,本发明的目的在于克服上述现有技术的不足之处而提供一种采用植物组分,消炎抗菌的效果相对温和有效,有很好的应用前景的抗炎舒缓类组合物及其应用。
为实现上述目的,本发明所采取的技术方案为:一种抗炎舒缓组合物,包含以下重量份的组分:八角茴香果提取物20-60份、八角茴香籽油1-5份和青钱柳叶提取物10-40份。
优选地,所述抗炎舒缓组合物,包含以下重量份的组分:八角茴香果提取物30-50份、八角茴香籽油2-4份和青钱柳叶提取物20-30份。
更优选地,所述抗炎舒缓组合物,包含以下重量份的组分:八角茴香果提取物40份、八角茴香籽油3份和青钱柳叶提取物25份。
八角茴香果实中含有丰富的黄酮类如槲皮素、山柰酚,酸类如莽草酸,厚朴酚,多糖类等多种活性物质,使其具有消炎抑菌、舒缓功效;另外八角茴香果中还含有挥发油,其主要成分为反式茴香脑(anethole)、樟烯(camphene)、芳樟醇(linalool)等,起抑菌防腐功效;青钱柳叶中含有丰富的多糖类、黄酮、萜类、蛋白质、矿物质、酚酸类、维生素和皂苷等多种活性物质,其中多糖类、黄酮类、酚酸类和皂苷类是主要的功效成分之一,具有抗氧化、抗菌消炎、舒缓的功效。
八角茴香果和青钱柳叶提取物都含有丰富的多糖类、酚酸类等活性成分,这些成分对皮肤具有舒缓消炎、抑菌的功效;而八角茴香籽油的主要活性成分是挥发油,其挥发油具有显著的抑菌作用,还有很强的穿透力快速的渗透到皮肤的深处,同时促进其余八角茴香果和青钱柳叶的吸收与渗透;但其用量不可过大,用量过大就有很强的辛辣感即刺热感刺激皮肤;过小效果不明显,因而需要三者的协同作用方可有很好的抗炎舒缓作用。
此外,本发明还提供所述抗炎舒缓组合物在化妆品中的应用。
同时,本发明还提供了包含所述抗炎舒缓组合物的抗炎舒缓类护肤品。
优选地,所述抗炎舒缓类护肤品,包含以下重量份的成分:抗炎舒缓组合物0.5-5份、保湿剂5-15份、乳化剂2-12份、增稠剂0.2-1.5份、油脂5-15份、防腐剂0.1-1.0份和pH调节剂0.1-0.4份。
优选地,所述抗炎舒缓类护肤品,包含以下重量份的成分:抗炎舒缓组合物3份、保湿剂8份、乳化剂7份、增稠剂0.9份、油脂10份、防腐剂0.6份和pH调节剂0.22份。
抗炎舒缓组合物重量份选择不可过多,因其具有抑菌作用,用量过多会影响皮肤微生态平衡;用量过小,效果不够明显;其余组分添加适合的重量份会得到肤感好的护肤品,用量或多或小会整个护肤品的肤感。
优选地,所述抗炎舒缓类护肤品,如下(a)-(c)中的至少一项:
(a)所述保湿剂为甘油、丁二醇、尿囊素、丙二醇、甜菜碱、泛醇、锁水磁石、透明酸钠和海藻糖中至少一种;
(b)所述乳化剂为鲸蜡硬脂醇、PEG-20硬脂酸酯、聚山梨醇酯-60、甘油硬脂酸酯、PEG-20甲基葡糖倍半硬脂酸酯、甲基葡糖倍半硬脂酸酯和硬脂醇聚醚-20中至少一种;
(c)所述增稠剂为卡波姆、黄原胶、聚乙二醇-160M和丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物中至少一种;
(d)所述油脂为角鲨烷,牛油果果脂、异壬酸异壬酯、霍霍巴籽油、环五聚二甲基硅氧烷和辛酸/癸酸甘油三酯中至少一种;
(e)所述防腐剂为苯氧乙醇和对羟基苯乙酮中至少一种;
(f)所述pH调节剂为三乙醇胺、氢氧化钠和氨甲基丙醇中至少一种。
进一步地,本发明还提供了一种抗炎舒缓类护肤品的制备方法,包括以下步骤:
(1)将油脂和乳化剂加入油相锅搅拌加热,至溶解透明,得到油相;
(2)将水、增稠剂和保湿剂依次加入水相锅中,均质加热,至完全溶解无颗粒,得到水相;
(3)将步骤(1)中制备得到的油相加入步骤(2)中制备得到的水相,进行搅拌、均质,保温,加入pH调节剂,得到混合液;
(4)将步骤(3)中制备得到的混合液,搅拌降温至40-45℃,依次加入抗炎舒缓组合物和防腐剂;最后搅拌降温至20-25℃,出料得到抗炎舒缓护肤品。
优选地,所述步骤(1)中,搅拌的速率为300-500r/min,加热的温度为70-80℃;所述步骤(2)中,均质的时间为3-5min,均质的速率为40-100r/min,加热的温度为85-90℃;所述步骤(3)中,搅拌的速率为1000-2000r/min,均质的时间为5-10min,均质的速率为200-300r/min,保温的时间为20-30min。
相对于现有技术,本发明的有益效果为:本发明使用八角茴香果提取物、青钱柳叶提取物都含有丰富的黄酮类化合物、有机酸类化合物,相互协同使其具有显著的抑菌消炎舒缓功效,再配以八角茴香油中挥发油,具有明显的抑菌效果,可以减少配方中防腐剂的使用,三者之间相互协同共同保证产品的安全性。
附图说明
图1为鸡胚试验过程中血管膜状态图;
其中,(a)为鸡胚试验加样品前的血管膜状态图;(b)为鸡胚试验加样品后的血管膜状态图。
具体实施方式
为更好的说明本发明的目的、技术方案和优点,下面将结合附图和具体实施例对本发明作进一步说明。
本发明抗炎舒缓类护肤品的实施例,实施例所述一种抗炎舒缓类护肤品,包含以下重量份的组分:抗炎舒缓组合物0.5-5份、保湿剂5-15份、乳化剂2-12份、增稠剂0.2-1.5份、油脂5-15份、防腐剂0.1-1.0份和pH调节剂0.1-0.4份。
所述抗炎舒缓类护肤品,制备方法包括如下步骤:
(1)将油脂和乳化剂加入油相锅搅拌加热,至溶解透明,得到油相;
(2)将水、增稠剂、保湿剂依次加入水相锅中,均质加热,至完全溶解无颗粒,得到水相;
(3)将步骤(1)中制备得到的油相加入步骤(2)中制备得到的水相,进行搅拌、均质,保温,加入pH调节剂,得到混合液;
(4)将步骤(3)中制备得到的混合液,搅拌降温至40℃,依次加入抗炎舒缓组合物、防腐剂;最后搅拌降温至25℃,出料得到抗炎舒缓护肤品。
本发明设置实施例1-5,具体实施例1-5制备抗炎舒缓护肤品过程中的组分选择如表1、表2和表3所示,对比例1-7中抗炎舒缓组合物的具体组分,如表4所示,其余组分与制备方法与实施例1完全相同。
表1实施例1-5中组分的重量份选择
表2实施例1-5中抗炎舒缓组合物的重量份选择
抗炎舒缓组合物 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 |
八角茴香果提取物 | 40 | 20 | 30 | 60 | 50 |
八角茴香籽油 | 3 | 1 | 2 | 5 | 4 |
青钱柳叶提取物 | 25 | 10 | 20 | 40 | 30 |
表3实施例1-5中其它组分的重量份选择
表4对比例中抗炎舒缓组合物的重量份选择
试验例1刺激性测试--鸡胚绒毛膜尿囊膜试验
参照SN/T 2329-2009化妆品眼刺激性/腐蚀性的鸡胚绒毛尿囊膜试验对实施例1-5及对比例1-7进行刺激性测试。
试验对象:孵化9d的受精鸡胚
试验过程:
一、选用孵化9d的受精鸡胚,在蛋壳表面标记气室位置;
二、用牙科锯齿弯镊剥去带标记的蛋壳部分、暴露白色蛋膜,用吸管滴加3mL NaCl质量分数为0.9%的氯化钠溶液使蛋膜湿润,小心用镊子去除内膜,保证血管膜不受损;
三、将实施例1-5及对比例1-7分别涂布于塑料薄膜表面,形成薄层,再将其覆盖于鸡胚绒毛尿囊膜上使受试物与绒毛尿囊膜直接接触,作用30min后去除薄膜。选用质量分数为0.9%的氯化钠溶液用于作用后的冲洗和阴性对照,冲洗30s后立即观察。
试验结果:参考SN/T 2329-2009对刺激性进行评分,如表5。
表5刺激性评分标准(出血)
刺激评分 | 刺激性分类 |
IS<1 | 无刺激性 |
1≤IS<5 | 轻刺激性 |
5≤IS<9 | 中度刺激性 |
IS≥10 | 强刺激性/腐蚀性 |
表6刺激性测试结果
从表6可以看出,对比例7的IS值为5.10,属于中度刺激,对比例1-6属于轻度刺激,而实施例的IS值均<1,属于无刺激性,且将实施例溶液涂布于鸡胚内膜清晰地分支血管处,如图1,5min后的血管无出血、溶血和凝血等现象出现。说明本发明的组合物对人体皮肤基本无刺激性,较为温和。
试验例2舒缓效果测试
试验对象:年龄在20-50周岁皮肤存在炎症如脱皮、红斑、瘙痒的志愿者130人,随机分成13组,每组10人。
试验过程:测试时间为1周,每天早晚各涂抹一次,涂抹本发明实施例1-5和对比例1-7制备的产品0.05mg/cm2,按摩至吸收,期间不可使用其他产品,同时设有空白组(不涂任何产品),1周后观察皮肤情况。
试验结果:皮肤状况分为3个级别:效果显著(无脱皮与红斑,皮肤光滑),效果一般(仅仅无脱皮和红斑),效果差(仍有脱皮与红斑),测试结果如表7。
表7舒缓效果测试结果
效果显著/人 | 效果一般/人 | 效果差/人 | |
实施例1 | 9 | 1 | 0 |
实施例2 | 7 | 3 | 0 |
实施例3 | 9 | 1 | 0 |
实施例4 | 8 | 2 | 0 |
实施例5 | 9 | 1 | 0 |
对比例1 | 1 | 4 | 5 |
对比例2 | 0 | 4 | 6 |
对比例3 | 0 | 7 | 3 |
对比例4 | 0 | 3 | 7 |
对比例5 | 0 | 2 | 8 |
对比例6 | 0 | 2 | 8 |
对比例7 | 0 | 1 | 9 |
空白 | 0 | 0 | 10 |
对比例1-3中抗炎舒缓组合物仅有一种,对比例4-6中抗炎舒缓组合物仅有两种,对比例7中无抗炎舒缓组合物,从表7可以看出,对比例7舒缓效果最差,对比例4-6的舒缓效果要比对比例1-3差,而实施例的舒缓效果要明显好于对比例,表明抗炎舒缓组合物有舒缓作用,且抗炎舒缓组合物三者的协同作用方可有很好的抗炎舒缓作用。
试验例3抑菌试验
试验对象:大肠杆菌ATCC8739;巴西曲霉ATCC16404
试验过程:
一、样品稀释:将上述的舒缓组合物样品用NaCl质量分数为0.9%的生理盐水都稀释成10%的样液。
二、制备样品滤纸:首先用打孔机打成直径6mm的圆片,灭菌后烘干,然后将滤纸浸泡于稀释的样液中,备用。
三、将5-10mL的生理盐水分别加入到培养细菌或霉菌的斜面试管内,反复吹吸,洗下菌苔;将洗下的菌苔稀释成105CFU/mL菌悬浮液。
四、在培养皿中倒入卵磷脂-吐温80营养培养基,待凝固,在培养基上倒入1mL含大肠杆菌ATCC8739(105CFU/mL)的菌悬浮液,均匀涂布在固体培养基上;另外在培养皿中倒入沙氏琼脂培养基,在培养基上倒入1mL含巴西曲霉ATCC16404(105CFU/mL)的菌悬浮液,均匀涂布在固体培养基上。
五、吸收凝固后,将样品滤纸分别放在细菌和霉菌培养基表面上,纸片间距24mm,距离培养皿边缘约15mm,每个培养皿放置4个。用生理盐水做对照。细菌37℃培养2天,霉菌28℃培养5天。最后用直尺测量抑菌圈直径,并记录其平均值。
试验结果:试验结果如表8
表8抑菌效果测试结果
对比例1-3中抗炎舒缓组合物仅有一种,对比例4-6中抗炎舒缓组合物仅有两种,对比例7中无抗炎舒缓组合物,从表8可以看出,对比例7抑菌效果最差,对比例4-6的抑菌效果要比对比例1-3差,而实施例的抑菌效果要明显好于对比例,表明抗炎舒缓组合物有抑菌作用,且抗炎舒缓组合物三者的协同作用方可有很好的抑菌作用。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种抗炎舒缓组合物,其特征在于,包含以下重量份的组分:八角茴香果提取物20-60份、八角茴香籽油1-5份和青钱柳叶提取物10-40份。
2.如权利要求1所述的抗炎舒缓组合物,其特征在于,包含以下重量份的组分:八角茴香果提取物30-50份、八角茴香籽油2-4份和青钱柳叶提取物20-30份。
3.如权利要求2所述的抗炎舒缓组合物,其特征在于,包含以下重量份的组分:八角茴香果提取物40份、八角茴香籽油3份和青钱柳叶提取物25份。
4.一种如权利要求1-3任一项所述抗炎舒缓组合物在化妆品中的应用。
5.一种抗炎舒缓类护肤品,其特征在于,包含权利要求1-3任一项所述抗炎舒缓组合物。
6.如权利要求5所述的抗炎舒缓类护肤品,其特征在于,包含以下重量份的成分:抗炎舒缓组合物0.5-5份、保湿剂5-15份、乳化剂2-12份、增稠剂0.2-1.5份、油脂5-15份、防腐剂0.1-1.0份和pH调节剂0.1-0.4份。
7.如权利要求6所述的抗炎舒缓类护肤品,其特征在于,包含以下重量份的成分:抗炎舒缓组合物3份、保湿剂8份、乳化剂7份、增稠剂0.9份、油脂10份、防腐剂0.6份和pH调节剂0.22份。
8.如权利要求6-7任一项所述的抗炎舒缓类护肤品,其特征在于,如下(a)-(f)中的至少一项:
(a)所述保湿剂为甘油、丁二醇、尿囊素、丙二醇、甜菜碱、泛醇、锁水磁石、透明酸钠和海藻糖中至少一种;
(b)所述乳化剂为鲸蜡硬脂醇、PEG-20硬脂酸酯、聚山梨醇酯-60、甘油硬脂酸酯、PEG-20甲基葡糖倍半硬脂酸酯、甲基葡糖倍半硬脂酸酯和硬脂醇聚醚-20中至少一种;
(c)所述增稠剂为卡波姆、黄原胶、聚乙二醇-160M和丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物中至少一种;
(d)所述油脂为角鲨烷,牛油果果脂、异壬酸异壬酯、霍霍巴籽油、环五聚二甲基硅氧烷和辛酸/癸酸甘油三酯中至少一种;
(e)所述防腐剂为苯氧乙醇和对羟基苯乙酮中至少一种;
(f)所述pH调节剂为三乙醇胺、氢氧化钠和氨甲基丙醇中至少一种。
9.一种如权利要求6-8任一项所述的抗炎舒缓类护肤品的制备方法,其特征在于,包括以下步骤:
(1)将油脂和乳化剂加入油相锅搅拌加热,至溶解透明,得到油相;
(2)将水、增稠剂、保湿剂依次加入水相锅中,均质加热,至完全溶解无颗粒,得到水相;
(3)将步骤(1)中制备得到的油相加入步骤(2)中制备得到的水相,进行搅拌、均质,保温,加入pH调节剂,得到混合液;
(4)将步骤(3)中制备得到的混合液,搅拌降温至40-45℃,依次加入抗炎舒缓组合物和防腐剂;最后搅拌降温至20-25℃,出料得到抗炎舒缓护肤品。
10.如权利要求9所述的抗炎舒缓类护肤品的制备方法,其特征在于,所述步骤(1)中,搅拌的速率为300-500r/min,加热的温度为70-80℃;所述步骤(2)中,均质的时间为3-5min,均质的速率为40-100r/min,加热的温度为85-90℃;所述步骤(3)中,搅拌的速率为1000-2000r/min,均质的时间为5-10min,均质的速率为200-300r/min,保温的时间为20-30min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010853665.2A CN111956547A (zh) | 2020-08-21 | 2020-08-21 | 一种抗炎舒缓类组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010853665.2A CN111956547A (zh) | 2020-08-21 | 2020-08-21 | 一种抗炎舒缓类组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111956547A true CN111956547A (zh) | 2020-11-20 |
Family
ID=73391103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010853665.2A Pending CN111956547A (zh) | 2020-08-21 | 2020-08-21 | 一种抗炎舒缓类组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111956547A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331928A (zh) * | 2000-08-22 | 2002-01-23 | 樊华轩 | 一种青钱柳叶保健食品及其制造方法 |
CN1520803A (zh) * | 2003-02-12 | 2004-08-18 | 江西省农学会 | 一种护肤组合物 |
JP2008255043A (ja) * | 2007-04-04 | 2008-10-23 | Nippon Menaade Keshohin Kk | 皮膚外用剤 |
JP2011201788A (ja) * | 2010-03-24 | 2011-10-13 | Nippon Menaade Keshohin Kk | 抗炎症剤 |
-
2020
- 2020-08-21 CN CN202010853665.2A patent/CN111956547A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331928A (zh) * | 2000-08-22 | 2002-01-23 | 樊华轩 | 一种青钱柳叶保健食品及其制造方法 |
CN1520803A (zh) * | 2003-02-12 | 2004-08-18 | 江西省农学会 | 一种护肤组合物 |
JP2008255043A (ja) * | 2007-04-04 | 2008-10-23 | Nippon Menaade Keshohin Kk | 皮膚外用剤 |
JP2011201788A (ja) * | 2010-03-24 | 2011-10-13 | Nippon Menaade Keshohin Kk | 抗炎症剤 |
Non-Patent Citations (4)
Title |
---|
柳海燕等: "青钱柳的生物活性成分及其药用价值", 《丽水学院学报》 * |
王同禹等: "八角茴香水溶性挥发成分的抑菌活性研究", 《中国调味品》 * |
王建新: "《化妆品植物原料大全》", 30 June 2012 * |
缪剑华等: "《南药与大南药》", 31 August 2014 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108158869B (zh) | 一种抑菌湿巾液、湿巾及其制备方法 | |
CN109157450B (zh) | 一种祛痘精华乳 | |
US20180116228A1 (en) | Antimicrobial traditional chinese medicine composition, and preparation method and use thereof | |
CN110051602B (zh) | 一种润肤保湿修复乳液及其制备方法 | |
CN112691055A (zh) | 一种去屑洗发水及其制备方法 | |
CN106973888A (zh) | 一种病理组织标本的保存液 | |
CN112006958A (zh) | 脱毛膏及制备方法 | |
CN105076253A (zh) | 一种黄瓜专用复合型生长调节剂 | |
CN106726998A (zh) | 一种含茶树花提取液的祛痘液 | |
CN110840768B (zh) | 一种艾草精华原液及其制备方法 | |
CN110613632B (zh) | 一种富含透明质酸或其盐的宠物洗护组合物及其制备方法 | |
CN111888306A (zh) | 一种祛黑头和修复酒糟鼻的精华液及其制备方法 | |
CN108186426B (zh) | 一种抑菌面膜液、面膜及其制备方法 | |
CN109453094B (zh) | 一种驱蚊止痒组合物及含有该组合物的护肤品 | |
CN114306162A (zh) | 一种化妆品用植物提取液的生产制备工艺及其应用 | |
CN111728913B (zh) | 一种多肽祛痘组合物及其制备方法与应用 | |
CN108295022B (zh) | 一种祛痘组合物及其制备方法 | |
CN104107154A (zh) | 一种化妆品组合物及其制备方法 | |
CN106377463A (zh) | 一种不含防腐剂的保湿爽肤水组合物 | |
CN116602896B (zh) | 一种天然植物防腐功效的自微乳化液及其制备方法 | |
CN107822962A (zh) | 一种婴儿适用的抗菌护手霜 | |
CN111956547A (zh) | 一种抗炎舒缓类组合物及其应用 | |
CN114522133B (zh) | 一种抑菌微乳液及其制备方法和应用、保湿水、保湿乳液、保湿膏霜及其制备方法 | |
CN107137316B (zh) | 一种石斛润唇膏及其制备方法 | |
CN105726448B (zh) | 一种含有多种蜂窝活性成分的护肤品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |
|
RJ01 | Rejection of invention patent application after publication |